United States

People: Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

18 Dec 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Shlevin, Harold 

Dr. Harold H. Shlevin has been appointed President, Chief Executive Officer, Chief Operating Officer effective July 6, 2018. Dr. Shlevin previously had been employed at the Georgia Institute of Technology’s Advanced Technology Development Center as Principle and Manager of bioscience commercialization efforts since November 2009, where he has assisted faculty in identifying technology worthy of commercialization, catalyzed formation of new start-up bioscience companies, and mentored new company management. From October 2008 to November 2009, he served as Head of Operations and Commercial Development for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water-soluble biotherapeutics and small drugs through the skin. At Altea, he was responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. From July 2006 to September 2008, Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics, Inc., a start-up pharmaceutical enterprise focused on later-stage development of neuroscience therapeutics. From May 2000 to January 2006, he served as President and CEO of Solvay Pharmaceuticals, Inc. (US). In January 2006, he was promoted to a global senior Vice President role within Solvay Pharmaceuticals, SA and member of the Board of Solvay Pharmaceuticals, SA.

Basic Compensation

Total Annual Compensation, USD 351,163
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 53,992
Fiscal Year Total, USD 405,155

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --